The Antivenom Interviews (target: Q4 2028) will be a sequel to The Venom Interviews (2016).
Development
The project is in early pre-production, with remaining principal photography planned for 2027 and post-production and release targeted for 2028. Substantial filming has already been completed in Mexico, Ghana, Togo, Benin, and Guinea. The remaining filming will take place in Costa Rica, Brazil, Denmark, France, the UK, Thailand, Indonesia, Australia, Nigeria, South Africa, India, and throughout the US.
The project is actively seeking investment to complete production and post-production.
Logline
Antivenom was born in the same scientific revolution that helped establish vaccines, antitoxins, and modern immunology — then remained anchored for more than a century to the same basic production model: animal-derived antibodies. The Antivenom Interviews follows this lifesaving technology from Pasteur-era serum therapy to the modern snakebite crisis, and to the breakthroughs that may finally reshape treatment for the next century.
Story Overview
PART I: From Infectious Diseases to Antivenom
Antivenom emerged in the late 1800s from the same immunological revolution that produced vaccines, antitoxins, and serum therapies. The fundamental process for producing it has remained the same for over a century, but that is finally changing.
PART II: Geographics: Who Dies Where, and Why
Snakebite is one of the world’s most neglected diseases, but outcomes are shaped by more than just snakes and their venom. Geography, poverty, medical training, supply chains, and access to care often determine who survives.
PART III: Toxins and Targets: How Venoms Work
Venoms are complex biochemical cocktails. They injure blood, tissue, and the nervous system, sometimes all at once. Every toxin acts in a different way, on different targets, and requires a different strategy to counteract its effects.
PART IV: Time is Tissue: Envenomation Syndromes, Measurement, and Treatment
Snakebite is a complicated medical emergency that requires immediate, skilled intervention. When clinicians have effective antivenom, basic medical equipment, and the training to use them, fatalities can be reduced by more than 95%.
PART V: Emerging Innovations
Advances in analytical technology are rapidly changing how scientists understand venoms. New ways of neutralizing venom toxins may expand clinicians’ options beyond traditional antivenom alone.